Evidence map›Paper›PMID 40682686›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Misrepresentation of semaglutide in social media.

Lara Elisabeth Propfe, Roland Seifert

Abstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lara Elisabeth PropfeInstitute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30655, Hannover, Germany.
Roland SeifertInstitute of Pharmacology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30655, Hannover, Germany. seifert.roland@mh-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, semaglutide has repeatedly attracted attention in the press and on social media due to its effects in weight management. The social media hype led to off-label use and global supply shortages. Our goal was to identify differences in the presentation of semaglutide on individual social media platforms. Additionally, we aim to investigate the mentioning of various aspects such as adverse drug reactions, drug indications, supply shortages, and costs. Current social media trends regarding semaglutide were also included in the analysis. We collected semaglutide-related posts from the social media platforms Instagram, TikTok, X, Facebook, and YouTube. The posts were then analysed and compared with the adverse drug reactions presented in the STEP trials. Semaglutide was presented by social media users almost exclusively for weight reduction. Misrepresentation of the pharmacological properties of semaglutide with respect to mechanism of action, indication, adverse effects, and drug interactions was very common on social media. The important aspect of treatment costs and supply shortages was barely covered, if at all. Most content creators on Instagram and TikTok were female semaglutide users without medical knowledge. Strikingly, the very common gastrointestinal problems during semaglutide therapy were not even mentioned on Instagram. Some of the posts found under the hashtag "ozempic" advertised products that did not contain semaglutide. Violations of the Medicinal Products Act were also identified. Videos of weight loss results have a high probability of artificial intelligence (AI) modification, which can lead to user deception. Social media often provides misleading information, especially regarding drug indications and adverse drug reactions. YouTube has emerged as the most reputable platform for medical information, whereas Instagram provides the least medical knowledge. Misinformation and AI-modified videos can negatively impact the self-perception of young social media users, leading to unreflected medication use.

Indexed as

Anti-Obesity AgentsGlucagon-Like PeptidesSocial MediaFemaleHumansOff-Label UseAnti-Obesity AgentsGlucagon-Like PeptidesGLP-1 receptor agonistOzempicSemaglutideSocial mediaType 2 diabetes mellitusWegovyWeight loss

Identifiers

PMID40682686
PMCPMC12894124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.